Recent advances in the treatment and monitoring of HIV-1 infection have substantially diminished HIV-associated illness and mortality;however the hepatitis C has emerged as a major co morbidity among HIV-infected patients. We are conducting studies that: (1) evaluate novel therapeutic strategies in the management of HCV-infected individuals, and (2) identify the host response characteristics that predict HCV response to existing treatment and aid in developing better future therapies. This past year, we were able to (1) determine the safety, tolerability and effectiveness of a novel regimen including twice monthly Albumin-Interferon alpha 2b along with Ribavirin to treat Hepatitis C in HIV co-infected subjects;(2) demonstrate the distinct influence of ongoing HIV replication on host immune activation profiles in Hepatitis C infected subjects;(3) demonstrate the effect of race, host genetics and baseline immune status (CD4+ T cell count) on response rates to HCV and adverse events using the pegylated Interferon-alpha and Ribavirin

Project Start
Project End
Budget Start
Budget End
Support Year
29
Fiscal Year
2012
Total Cost
$441,974
Indirect Cost
City
State
Country
Zip Code
Lee, Yu-Jin; Zhang, Xiaozhen; Vazquez, Estefania et al. (2014) Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFN?R2a. J Interferon Cytokine Res 34:28-34
Meissner, Eric G; Bon, Dimitra; Prokunina-Olsson, Ludmila et al. (2014) IFNL4-?G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 209:1700-4
Fauci, Anthony S; Marovich, Mary A; Dieffenbach, Carl W et al. (2014) Immunology. Immune activation with HIV vaccines. Science 344:49-51
Kohli, Anita; Shaffer, Ashton; Sherman, Amy et al. (2014) Treatment of hepatitis C: a systematic review. JAMA 312:631-40
Osinusi, Anu; Bon, Dimitra; Nelson, Amy et al. (2014) Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients. J Med Virol 86:177-85
Meissner, Eric G; Wu, David; Osinusi, Anu et al. (2014) Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 124:3352-63
Katsounas, Antonios; Rasimas, Joseph J; Schlaak, Joerg F et al. (2014) Interferon stimulated exonuclease gene 20?kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients. J Med Virol 86:1323-31
Kapoor, Rama; Kottilil, Shyam (2014) Strategies to eliminate HBV infection. Future Virol 9:565-585
Odigie, Madeline; Osinusi, Anu; Barrett, Lisa et al. (2014) Inteleukin-23 promotes interferon-? responsiveness in hepatitis C virus/HIV-coinfected patients. AIDS Res Hum Retroviruses 30:775-82
Sidharthan, Sreetha; Kottilil, Shyam (2014) Mechanisms of alcohol-induced hepatocellular carcinoma. Hepatol Int 8:452-7

Showing the most recent 10 out of 50 publications